Introduction
Non-Hodgkin's lymphoma is a heterogeneous group of B-and T-cell cancers, with a large variety of patterns of growth, clinical presentations and responses to treatment. Outcome depends on histological subtype, tumor characteristics host responses and treatment. About 90% of lymphomas have a B-cell phenotype and for them recent therapeutic progress came from the introduction of monoclonal antibodies (MAb) alone or in combination with chemotherapy (Coiffier, 2005a,b; Traulle and Coiffier, 2005) . The first antigen that has been targeted for therapeutic purpose with success was the CD20 antigen, a transmembrane protein expressed by more than 99% of B-cell lymphomas. Rituximab was the first MAb engineered to target the CD20 antigen and the first approved MAb for the treatment of lymphoma patients. Through the last 10 years clinical trials with rituximab have confirmed its efficacy in follicular lymphoma (FL) as well as in aggressive lymphomas and its use has expanded significantly beyond the initial indication of indolent B-cell lymphomas to virtually any CD20-positive lymphoma.
Mechanisms of action of rituximab
The mechanisms of action of MAb differ with the type of antibody, the antigen they target and their use: alone, in combination with chemotherapy, conjugated to a toxin or a radionucleide. In case of rituximab, different mechanisms have been identified (Cartron et al., 2004) . CD20 binding by rituximab is followed by homotypic aggregation, rapid translocation of CD20 into specialized plasma membrane microdomains known as rafts and induction of apoptosis. Membrane rafts concentrate src family kinases and other signaling molecules (phospholipases, caspases y), and the anti-CD20-induced apoptotic signals are though to occur as a consequence of CD20 accumulation in rafts (Janas et al., 2005) . The role of complement-dependent cytotoxicity (CDC) is suggested by the consumption of complement observed after rituximab administration but in vitro CDC does not correlate with clinical response in lymphomas (Winkler et al., 1999; Weng and Levy, 2001 ). However, CDC seems to be the most important mechanism of cell lysis in chronic lymphocytic leukemia (CLL) patients (Kennedy et al., 2004) . CDC is probably involved in the cytokine-release syndrome and its toxicity (Bienvenu et al., 2001) .
The importance of antibody-dependent cellular cytotoxicity (ADCC) has been demonstrated in vivo when rituximab is used alone (Cartron et al., 2002) . The Fc receptor (FcgR) of effector cells has two alleles and the valine/valine (V/V) allele of FcgRIIIa that confers a higher affinity for IgG1 and rituximab is associated with an increase responsiveness to rituximab (Cartron et al., 2002; Weng and Levy, 2003) . If the clinical relevance of the FcgRIIIa receptor dimorphism was established in a number of studies with rituximab used alone, it does not seem to play a major role when rituximab is used in combination with chemotherapy (Boettcher et al., 2004) even if one study showed an increased response for patients with the V/V allele without difference for progression-free survival (PFS) or overall survival (OS) (Kim et al., 2006) .
Finally, evidences that rituximab could synergize with chemotherapeutic agents in B-cell killing were provided by Demidem et al. (1997) . Subsequent investigations have confirmed synergy of rituximab with fludarabine, doxorubicin and other anticancer drugs (Alas et al., 2000; Alas and Bonavida, 2001; Ghetie et al., 2001) . In one hypothesis, this synergism is mediated, at least in part, via downregulation of interleukin-10 (IL-10) by rituximab, which in turn causes downregulation of the antiapoptotic protein bcl2 and increased sensitivity to apoptosis (Vega et al., 2004) . Another mechanism involves the inhibition of the activity of P-glycoprotein and, thus, the efflux of drugs like doxorubicin or vincristine (Ghetie et al., 2006) . In cell lines, the Pglycoprotein pump is translocated out of the lipids rafts. This activity seems independent of the classical antiproliferative effect of rituximab (Ghetie et al., 2006) .
Mechanisms of resistance
If multiple mechanisms of rituximab action have been reported, it remains unclear which is/are most important in patients, and therefore it is difficult to know the relative importance of potential mechanisms of resistance. Conceptual approaches of resistance mechanisms may be resumed as followed (Smith, 2003) .
Concerning events up to antigen binding, resistance to rituximab may be secondary to low-serum levels or rapid metabolism of the MAb; development of antimonoclonal antibodies (HAMA), most frequent with nonhumanized antibodies than with rituximab or antichimeric (HACA) antibodies (not yet demonstrated in patients); possibly different distribution within malignant nodes, blood cells, marrow and extranodal sites and responsible for poor tumor penetration; high level of soluble antigen target (not yet demonstrated for CD20 antigen); high tumor burden; and poor surface antigen expression.
Events that may induce resistance to rituximab after the antigen binding are alteration of induced intracellular signals; reduction of direct apoptosis effect in cases of elevated bcl-2 protein; inhibition of CDC by complement inhibitors; and alteration of cell-mediated immunity. Gene microarray analysis has shown that patients who failed to respond to rituximab have altered patterns of gene expression, with an overexpression of genes important in cell-mediated immunity (Bohen et al., 2003) .
Safety and tolerability
The safety of rituximab is mainly related to infusion toxicity, a toxicity most MAb have in common (Kimby, 2005) . These side effects are observed during the infusion or in the first hours after drug infusion and particularly for the first infusion. They include fever, chills, dizziness, nausea, pruritus, throat swelling, cough, fatigue, hypotension and transient bronchospasm in a majority of patients. These symptoms are part of the cytokine-release syndrome. Their intensity correlates with the number of circulating malignant cells at time of infusion. More severe infusional toxicity includes bronchospasm, angioedema and acute lung injury, often associated with high circulating cell counts or preexisting cardiac or pulmonary disease.
Another common toxicity is the rapid depletion of normal CD20-positive B lymphocytes from blood, bone marrow and lymph nodes of the recipient, lasting between 3 and 6 months following the last administration of rituximab. In the case of short rituximab treatment, this depletion does not compromise immunity: immunoglobulins do not decrease significantly, and patients do not have an increased risk for infections during and after rituximab therapy Kimby, 2005) , except for some virus like herpes virus, cytomegalovirus or hepatitis B virus. Maintenance treatment, particularly after autologous transplant, might be associated with a decrease in immunoglobulins (Lim et al., 2004) and late toxicity (Kimby, 2005) .
Rare toxic events comprised delayed neutropenia and pulmonary reactions. Delayed neutropenia usually occurs in patients treated with rituximab alone or in combination with chemotherapy. It appears between 1 and 6 months after the last infusion, may be transient, rarely associated with infection and resolve spontaneously in most of the cases (Lemieux et al., 2004b) . The mechanisms are not fully understood. Pulmonary reactions are rare and diverse, usually related to rituximab because of the temporal relation (Kimby, 2005) . I-tositumomab (Bexxar), and denileukin diftitox (OnTak), the last two only in the USA. However, a lot of other MAb are currently in preclinical studies, phase I or phase II studies. Rituximab is certainly the MAb where the largest experience exists and the MAb with several demonstrative randomized studies.
Rituximab in FL
Rituximab alone in relapse When used alone, rituximab is usually given as four weekly injections of 375 mg/m 2 (Maloney, 1999) . The pivotal multicentre phase II study that included 166 patients treated with four infusions of rituximab showed an overall remission rate of 48% (including 6% of CR), and a median time to progression of 13 months (McLaughlin et al., 1998) . Elevated b2-microglobulin, elevated LDH, bulky disease and age >60 years did not appear to impact response, implying that patients regarded as having a poor prognosis may respond to rituximab. Median rituximab serum levels were significantly higher in responders, compared with the non-responders (Berinstein et al., 1998) . Mean serum antibody concentration was inversely correlated with the bulk of the disease and the number of circulating B cells, suggesting that patients with a higher tumor load might need higher doses or prolonged treatment, to achieve the necessary serum levels (Gordan et al., 2005) .
Patients relapsing after initial response to rituximab treatment may be retreated with comparable response rates (RR) and adverse side effects, but, interestingly, median time for progression might be longer than after first treatment (Davis et al., 2000a; Lemieux et al., 2004a) . Patients who progressed after rituximab retreatment respond again to further courses (Lemieux et al., 2004a) .
Whether rituximab prolonged treatment or maintenance is able to further improve RR and to prolong remission duration is of considerable interest. Several arguments are in favor of this approach: the success of re-treatment or the strong correlation between rituximab plasma levels and RR (Berinstein et al., 1998) . A recent randomized trial showed that adding maintenance doses of rituximab prolonged response duration (Ghielmini et al., 2004) : 202 patients with newly diagnosed or refractory/relapsed FL were treated with standard rituximab (375 mg/m 2 weekly Â 4). Patients responding, or with stable disease, were randomized to no further treatment or prolonged rituximab administration (375 mg/m 2 every 2 months for four times). With a median follow-up of 35 months, the median event-free survival (EFS) was prolonged in the treated group, 23 months vs 12 months in the control group. In a nonrandomized prospective study, prolonged treatment in first-line patients seems also associated with a higher and longer efficacy (Hainsworth, 2004) . However, in both studies, patients relapsed within the 6 months after stopping rituximab treatment. In another randomized study, Hainsworth et al. (2005) showed that retreatment at relapse or prolonged treatment have the same benefit in terms of duration of rituximab efficacy or time to chemotherapy.
Several questions remain without clear response: what is the optimal prolonged treatment? What is the optimal duration maintenance? Which patients benefit from prolonged treatment? And, finally, is prolonged treatment or retreatment at progression better in terms of survival or impact on transformation rate?
Rituximab alone in untreated FL Usually, patients with no adverse prognostic factors are not treated until they develop such adverse parameters (Ardeshna et al.,. 2003) . However, because of its low profile toxicity, its presumed low rate of secondary malignancy and its lack of stem cell toxicity, rituximab single agent was investigated in this setting (Colombat et al., 2001) : in a series of 50 patients, a RR of 73% was obtained, with 26% of CR; 57% of the informative patients in CR reached a molecular remission. However, even patients in CR and in molecular response did not seem to benefit from this treatment because the median time to progression was only 2 years, not longer than without treatment. A 5-year follow-up of this study showed that some patients (34% of responders) may have a relapse-free survival longer than 5 years and an excellent OS for all patients: only three deaths (SolalCeligny et al., 2004) . A randomized study is currently underway in UK challenging this finding in these otherwise 'watch and wait' patients.
Rituximab alone was also studied in patients with a more aggressive presentation, needing treatment at diagnosis or after some follow-up without treatment (Hainsworth et al., 2002) . The RR, just after four infusions, was comparable with the one observed in relapsing patients (50% and less than 10% of CR). About 10% of patients had progressive disease during the immediate post-treatment period and progression occurred in less than 12 months among 50% of the responding patients. If this schedule has the favor of some physicians because it avoids chemotherapy, results are quite inferior to combination of chemotherapy and rituximab (see below) and no indication has yet been given regarding OS. In our opinion, it should not be the recommended choice of treatment until randomized trials have compared it to the combined treatment.
In another study, Hainsworth et al. (2005) compared prolonged treatment to retreatment at demand and did not show any benefit in terms of duration of rituximab response or time to chemotherapy. This study has several drawbacks, among them an early termination and a lack of power to conclude. Thus the Eastern Cooperative Group has launched the RESORT study (rituximab extended schedule or retreatment trial) to clarify this question (Kahl, 2006) .
Rituximab in combination with chemotherapy
In a phase II study, the combination of six cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) with rituximab given before, during, and after chemotherapy in 40 patients with predominantly untreated FL increased the RR (55% CR and 40% PR), with no added related toxicity (Czuczman et al., 2005) . Median time to progression was 82 months.
Several randomized studies have now demonstrated that the addition of rituximab to a standard chemotherapy regimen results in higher RR and longer time to progression and EFS for patients treated with a combination of rituximab plus chemotherapy in firstline or in first-relapse (Table 1) . In first line patients, four studies have reported a benefit in terms of CR rates and PFS, although an OS benefit was only showed in the two studies using a doxorubicin-containing regimen (Herold, 2004; Salles et al., 2004; Hiddemann et al., 2005; Marcus et al., 2005) . The first study randomized patients between eight cycles of cyclophosphamide, vincristine and prednisone CVP and R-CVP (Marcus et al., 2005) . Overall and CR rates were 81 and 41% in the R-CVP arm vs 57 and 10% in the CVP arm, respectively (Po0.0001). At a median follow-up of 53 months, patients treated with R-CVP had a highly significantly prolonged time to progression (median 32 months vs 15 months for CVP; Po0.0001). Median time to treatment failure was 27 months in patients receiving R-CVP and 7 months in the CVP arm (Po0.0001). OS was longer for R-CVP than CVP (19 vs 29% patients died, P ¼ 0.03) .
In the second study, patients were randomized between six cycles of cyclophosphamide þ doxorubicin þ vincristine þ prednisolone (CHOP) and rituximab (R)-CHOP (Hiddemann et al., 2005) . In 428 patients, R-CHOP revealed a significantly higher RR (96 vs 90%, P ¼ 0.011) and a longer treatment failure (TTF) (median not reached vs 2.6 years, Po0.0001). In the second German study, patients with indolent lymphoma (56% follicular) were randomized between six cycles of MCP (mitoxantrone, cyclophosphamide and prednisone) and R-MCP (Herold, 2004) . The overall RR and the CR for all patients was 85.5 and 42% in the R-MCP arm versus 65.5% and 20% in the MCP arm (Po0.0001). EFS was significantly prolonged for patients receiving R-MCP vs MCP alone (Po0.001). Median EFS for MCP was 19 months and 73% for R-MCP. Follow-up was too short in these two studies for studying OS.
In the French study, patients were randomized between CHVP þ interferon for 18 months and R-CHVP þ interferon Foussard et al., 2006) . This first analysis of all patients demonstrated a significant improvement of response to therapy with R-CHVP þ interferon compared to CHVP þ interferon, both at 6 months (CR þ CRru 49 vs 76%; PR 36 vs 18%; respectively (Po0.0001)) and at 18 months (CR þ CRu 79% vs 63%; PR 5 vs 10%; respectively (P ¼ 0.004)). In the control arm, estimated 3.5 years EFS was 46 vs 67% with R-CHVP þ interferon (Po0.0001). Even if the median follow-up is only 3.5 years, this study showed a statistically significant OS advantage for patients treated with rituximab (91 compared to 84% surviving at 3.5 years, P ¼ 0.029).
In relapsing patients, the fudarabine cyclophosphamide and mitoxantrone (FCM) study showed that R-FCM is superior to FCM alone for relapsing patients with FL or mantle cell lymphoma (MCL) (Forstpointner et al., 2004 ). An update of this study showed that responding patients, treated either with FCM or R-FCM had a prolonged PFS if they received a maintenance with rituximab (Forstpointner et al., 2006) . The EORTC study compared R-CHOP and CHOP alone in first-or second-line patients not previously treated with doxorubicin (van Oers et al., 2006) . This last study is particularly interesting because preliminary results showed a benefit of R-CHOP over CHOP but also a benefit of rituximab maintenance after CHOP only induction. Rituximab maintenance yielded a median PFS from second randomization of 51.5 months versus 15 months with observation (HR, 0.40; Po0.001). Improved PFS was found both after induction with CHOP (HR, 0.30; Po0.001) and R-CHOP (HR, 0.54; P ¼ 0.004). R maintenance also improved OS from second randomization: 85% at 3 years versus 77% with observation (HR, 0.52; P ¼ 0.011).
The German study in relapsing patients with FLs and MCLs looked at the effect of rituximab maintenance after salvage with FCM or R-FCM (Forstpointner et al., 2006) . The first randomization was stopped after 147 patients when an interim analysis showed a statistically significant advantage for R-FCM over FCM. Patients continued to enter the R-FCM arm for the second randomization, with or without maintenance. Response duration was significantly prolonged Finally, one study reported that maintenance with rituximab in patients treated with chemotherapy increases CR rates and prolongs PFS (Hochster et al., 2004) . However, the role of rituximab maintenance after a combination of rituximab plus chemotherapy in firstline patients remains unclear and it is not currently recommended in CR patients.
These different studies have implemented the use of combining rituximab with chemotherapy as standard treatment in patients with FL who need to be treated. Which of the chemotherapy regimens is better is not yet demonstrated but the comparison of CR rates, EFS, PFS and OS from the different studies seems to show a larger benefit with the R-CHOP regimen. The comparison of results obtained with R-CHOP to those reached with rituximab only in the same type of patients equally favors the use of R-CHOP. However, these conclusions need to be taken with caution because no randomized study has compared these different regimens.
Rituximab in combination with cytokines
Interferon a2 has a direct antilymphoma activity but it may also upregulate CD20 antigen expression on lymphoma cells and, then, potentially augments the immune response induced by rituximab (Portlock et al., 2006) . Hence, its combination with rituximab could potentially represent an alternative to the rituximabchemotherapy combinations. Currently, only phase II studies or preliminary data are available preventing any definitive conclusions (Davis et al., 2000b; Kimby, 2002) . Phase I trials combining rituximab with other cytokines such as IL-2, IL-12, granulocyte-colony stimulating factor and granulocyte macrophage colonystimulating factor have shown promising preliminary results that need to be confirmed in phases II trials (van der Kolk et al., 2002; Eisenbeis et al., 2004) .
Rituximab in diffuse large B-cell lymphoma
The combination regimen R-CHOP, consisting of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone), is now considered as the standard treatment for treating young and elderly patients with diffuse large B-cell lymphoma (DLBCL) because of the superior activity demonstrated in three randomized studies (Table 2) . Results from the GELA study have been recently updated with a 5-year median follow-up and showed a persisting advantage for patients treated with R-CHOP (Table 3) (Coiffier et al., 2002; Feugier et al., 2005) . In this study, patients with DLBCL and aged 60-80 years were treated either with eight cycles of CHOP or eight cycles of R-CHOP. The difference observed between the two arms was already statistically significant for EFS, PFS and OS with a median follow-up of 1 year and improve with follow-up (Figure 1) .
The MInT study compared in 824 patients six cycles of R-CHOP-like chemotherapy to CHOP-like in young patients with a low-risk DLBCL (Pfreundschuh et al., 2006) . After a median time of follow-up of 34 months, R-CHEMO patients had a significantly longer (TTF) 
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(Po0.00001), with estimated 2-year TTF rates of 60% (CHEMO) vs 76% (R-CHEMO). Complete remission rates of evaluable patients (CR) were significantly different (67% CHEMO vs 81% R-CHEMO, Po0.0001) as were the rates of progressive disease during treatment (15% vs 4%, Po0.00001). Similarly, overall survival was significantly different (Po0.001), with 2-year survival rates of 87% (CHEMO) and 94% (R-CHEMO), respectively. The American study (ECOG/SWOG/CALGB study) was associated with a statistically benefit in the primary end point time to TTF for the addition of rituximab to CHOP vs CHOP alone . However, the complicated design of this study makes conclusions difficult compared to the two other studies. Furthermore, the administration of significantly less rituximab compared to the other studies may very well have contributed to the somewhat inferior results. The interesting point of this study is the second randomization looking at the effect of rituximab in patients who reached a CR or a PR. If rituximab maintenance may decrease the progression rate in patients treated with CHOP only, it has no effect on patients treated with R-CHOP. This was the only study looking at rituximab maintenance in DLBCL in first line but the analysis of this negative study is difficult because of its poor design and it must be tested in patients at risk, particularly relapsing patients after autologous transplant.
In a population-based analysis, the impressive efficacy results of the GELA trial can be as well repeated as the safety results be confirmed (Sehn et al., 2005) : outcomes for patients with DLBCL were compared between two periods, CHOP then R-CHOP treatment recommendations. Both PFS (risk ratio, 0.56; 95% CI 0.39-0.81; P ¼ 0.002) and OS (risk ratio, 0.40; 95% CI 0.27-0.61, Po0.0001) were significantly improved in the postrituximab group.
If this R-CHOP regimen had a great activity in good risk patients, progresses still have to be made in the group of poor-risk patients. Several ways are currently been tested such dose-dense and dose-intense regimens or the association of other biologics (Coiffier and Reyes, 2005; Coiffier, 2005c Coiffier, , 2006 . One interesting observation was the fact that prognostic parameters such as those described in the International Prognostic index seem to loose some importance in patients treated with R-CHOP (Sehn et al., 2007) . Even the new prognostic parameters described with microarray gene analyses are less important than bcl-2 or bcl-6 protein expression (Farinha et al., 2006; Mounier et al., 2006; Winter et al., 2006) . However, which parameters are associated with the risk of recurrence and dying in patients treated with R-CHOP is not yet described.
Rituximab in other lymphomas
Small lymphocytic lymphoma The efficacy of rituximab alone in this lymphoma is not very well known, with few and discordant results. In a European study in relapsing patients, the efficacy was low, with only a 10% RR (Foran et al., 2000) . In untreated patients, in contrast, found a 51% RR after four injections, with only 4% CR, and a median PFS of 18 and 6 months Hainsworth et al. (2003) . Further studies are warranted to define the modality of use of rituximab monotherapy in this lymphoma, and its possible benefit. As small lymphocytic leukemia is closely related to CLL, the use of rituximab in combination with fludarabine and/or cyclophosphamide should be tested because of its efficacy in CLL patients (Keating et al., 2005) .
Marginal zone lymphoma
Mostly case reports have shown an efficacy of rituximab in these lymphomas, which seems comparable to what is observed in FL (Paydas et al., 2003) . Efficacy was demonstrated in relapsing mucosa-associated lymphoid tissue (MALT) lymphoma (Conconi et al., 2003) . A current International Extranodal Lymphoma Study Group trial randomizes chlorambucil vs chlorambucil þ rituximab in new or relapsing patients with MALT lymphoma.
Mantle cell lymphoma MCL has indolent lymphoma characteristics, but tends to pursue an aggressive clinical course and is incurable with standard chemotherapy. An interim analysis of a (Forstpointner et al., 2004) . Interestingly, about one-third of the patients achieved a molecular remission. A maintenance with rituximab was scheduled for responding patients and allow to prolong the duration of response (Forstpointner et al., 2006) . Long-term remissions have been reported with intensive chemotherapy and autologous stem-cell transplantation (ASCT) plus rituximab (see below).
Chronic lymphocytic leukemia (CLL)
Rituximab, given weekly as a single agent has low activity in relapsing patients with CLL. A better activity has been observed in untreated patients (Hainsworth et al., 2003) . Dose escalation, achieved by a thriceweekly dosing schedule (Byrd et al., 2001) , or higher weekly doses, 500-2250 mg/m 2 (O'Brien et al., 2001) , is necessary to reach significant clinical activity, with a RR of respectively 45 and 36%, as a single agent. The concurrent administration of rituximab with fludarabine resulted in better results with a RR rate of 90%, with 47% CR (Byrd et al., 2003) . Ongoing clinical studies are examining the use of rituximab associated with fludarabine and cyclophosphamide, which has shown great promise in a single-center phase II study (Keating et al., 2005; Wierda et al., 2005 ). An historical comparison among two studies from the CALGB showed that in multivariate analyses controlling for pretreatment characteristics, the patients receiving fludarabine and rituximab had a significantly better PFS (Po0.0001) and OS (P ¼ 0.0006) than patients receiving fludarabine therapy (Byrd et al., 2005) . Two year PFS probabilities were 0.67 vs 0.45, and 2-year OS probabilities were 0.93 vs 0.81.
Other lymphomas
Rituximab has been used successfully in lymphocyte predominant Hodgkin's lymphoma or classical Hodgkin's lymphoma (Ekstrand et al., 2003; Rehwald et al., 2003; Younes et al., 2003) . Few phase II studies exist for Burkitt's lymphoma: results regarding response and relapse seems good but it is difficult to know the improvement secondary to rituximab use (Thomas et al., 2006) . In post-transplant lymphoproliferative disease several phase II have shown a good activity with rituximab alone or in combination with chemotherapy (Milpied et al., 2000; Blaes et al., 2005; Jain et al., 2005) .
The only yet reported randomized study without benefit in the rituximab arm was in patients with human immunodeficiency virus -associated lymphoma: the RR was not statistically different in R-CHOP or CHOP arms (Kaplan and Scadden (2004) ). However, this study did not have the power to show a significant difference and the follow-up is extremely short. In another phase II study, R-CHOP produced a CR rate of 77% and a 2-year survival rate of 75% without severe infectious complications (Boue et al., 2006) .
MAb and high-dose therapy with ASCT
Rituximab has been used as an in vivo purging agent before and as maintenance therapy after ASCT, in FL and MCL (Gianni et al., 2003; Belhadj et al., 2004) and in aggressive lymphoma (Horwitz and Horning, 2004) , in first line or in relapse, with promising results. An ongoing international trial in relapsed and refractory aggressive lymphoma randomizes rituximab (dexamethasone, aracytine, cisplatin) vs rituximab (ifosfamide, carboplatin, etoposide) before ASCT and with a second randomization between rituximab maintenance and observation (CORAL study) (Hagberg and Gisselbrecht, 2006) . Rituximab given after ASCT might have the interest to complete the remission and to further decrease the relapse rate. In a German study, CR rates developed overtime (57% at 6 months and 88% at 12 months), and after 2 years 29 out of 30 patients were in persistent CR, whereas molecular response increased from 22% pretransplant to 72% 4 weeks after rituximab and 100% 6 months after transplantation (Brugger, 2004) . However, this treatment may be associated with more infections (Neumann et al., 2006) . It had been associated with severe decrease in immunoglobulin levels (Lim et al., 2005) and more frequent neutropenia (Lemieux et al., 2004b) .
Conclusion
Rituximab was the first Mab registered in the treatment of lymphomas and it has allowed one of the major progresses for the treatment of lymphoma patients. Alone, it is a very well-tolerated drug and it has a great activity in relapsing patients. However, it will hardly result in cure in this setting. In combination with chemotherapy, rituximab allowed for the highest RRs and longest EFs and OS ever described in follicular and DLBCL. It has activity but less well demonstrated in other B-cell lymphomas. Other Mabs targeting CD20 or other antigens are on their way but their activity is not yet well defined compared to rituximab. 
